These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 31275144)

  • 1. Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa-Induced Dyskinesia
    Wang WW; Zhang XR; Lin JY; Zhang ZR; Wang Z; Chen SY; Xie CL
    Front Pharmacol; 2019; 10():660. PubMed ID: 31275144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats.
    Zhang ZR; Zhang XR; Luan XQ; Wang XS; Wang WW; Wang XY; Shao B; Xie CL
    Neurochem Int; 2019 Dec; 131():104543. PubMed ID: 31491493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-arrestin2 alleviates L-dopa-induced dyskinesia via lower D1R activity in Parkinson's rats.
    Zhang XR; Zhang ZR; Chen SY; Wang WW; Wang XS; He JC; Xie CL
    Aging (Albany NY); 2019 Dec; 11(24):12315-12327. PubMed ID: 31891566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.
    Xie CL; Wang WW; Zhang SF; Yuan ML; Che JY; Gan J; Song L; Yuan WE; Liu ZG
    Sci Rep; 2014 Dec; 4():7506. PubMed ID: 25511986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Levodopa/Benserazide Loaded Microspheres Alleviate L-dopa Induced Dyskinesia through Preventing the Over-Expression of D1R/Shp-2/ERK1/2 Signaling Pathway in a Rat Model of Parkinson's Disease.
    Wan Y; Wu N; Song L; Wang X; Liu Z; Yuan W; Gan J
    Front Aging Neurosci; 2017; 9():331. PubMed ID: 29093677
    [No Abstract]   [Full Text] [Related]  

  • 6. 5-Hydroxy-tryptophan for the treatment of L-DOPA-induced dyskinesia in the rat Parkinson's disease model.
    Tronci E; Lisci C; Stancampiano R; Fidalgo C; Collu M; Devoto P; Carta M
    Neurobiol Dis; 2013 Dec; 60():108-14. PubMed ID: 24004632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting β-arrestin2 in the treatment of L-DOPA-induced dyskinesia in Parkinson's disease.
    Urs NM; Bido S; Peterson SM; Daigle TL; Bass CE; Gainetdinov RR; Bezard E; Caron MG
    Proc Natl Acad Sci U S A; 2015 May; 112(19):E2517-26. PubMed ID: 25918399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selegiline increases on time without exacerbation of dyskinesia in 6-hydroxydopamine-lesioned rats displaying l-Dopa-induced wearing-off and abnormal involuntary movements.
    Tsunekawa H; Takahata K; Okano M; Ishikawa T; Satoyoshi H; Nishimura T; Hoshino N; Muraoka S
    Behav Brain Res; 2018 Jul; 347():350-359. PubMed ID: 29526790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The abnormal activation of D1R/Shp-2 complex involved in levodopa-induced dyskinesia in 6-hydroxydopamine-lesioned Parkinson's rats.
    Wu N; Wan Y; Song L; Qi C; Liu Z; Gan J
    Neuropsychiatr Dis Treat; 2018; 14():1779-1786. PubMed ID: 30013350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of memantine on L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson's disease.
    Tronci E; Fidalgo C; Zianni E; Collu M; Stancampiano R; Morelli M; Gardoni F; Carta M
    Neuroscience; 2014 Apr; 265():245-52. PubMed ID: 24486947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The involvement of RGS9 in l-3,4-dihydroxyphenylalanine-induced dyskinesias in unilateral 6-OHDA lesion rat model.
    Yin LL; Geng XC; Zhu XZ
    Brain Res Bull; 2011 Nov; 86(5-6):367-72. PubMed ID: 21963945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcium-permeable AMPA receptors are involved in the induction and expression of l-DOPA-induced dyskinesia in Parkinson's disease.
    Kobylecki C; Cenci MA; Crossman AR; Ravenscroft P
    J Neurochem; 2010 Jul; 114(2):499-511. PubMed ID: 20456008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential induction of dyskinesia and neuroinflammation by pulsatile versus continuous l-DOPA delivery in the 6-OHDA model of Parkinson's disease.
    Mulas G; Espa E; Fenu S; Spiga S; Cossu G; Pillai E; Carboni E; Simbula G; Jadžić D; Angius F; Spolitu S; Batetta B; Lecca D; Giuffrida A; Carta AR
    Exp Neurol; 2016 Dec; 286():83-92. PubMed ID: 27697481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alternative splicing of AMPA receptor subunits in the 6-OHDA-lesioned rat model of Parkinson's disease and L-DOPA-induced dyskinesia.
    Kobylecki C; Crossman AR; Ravenscroft P
    Exp Neurol; 2013 Sep; 247():476-84. PubMed ID: 23360800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The 5-alpha reductase inhibitor finasteride reduces dyskinesia in a rat model of Parkinson's disease.
    Frau R; Savoia P; Fanni S; Fiorentini C; Fidalgo C; Tronci E; Stancampiano R; Meloni M; Cannas A; Marrosu F; Bortolato M; Devoto P; Missale C; Carta M
    Exp Neurol; 2017 May; 291():1-7. PubMed ID: 28131725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal mRNA expression patterns underlying peak dose L-DOPA-induced dyskinesia in the 6-OHDA hemiparkinsonian rat.
    Smith LM; Parr-Brownlie LC; Duncan EJ; Black MA; Gemmell NJ; Dearden PK; Reynolds JN
    Neuroscience; 2016 Jun; 324():238-51. PubMed ID: 26968766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intrastriatal inhibition of aromatic amino acid decarboxylase prevents l-DOPA-induced dyskinesia: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine lesioned rats.
    Buck K; Ferger B
    Neurobiol Dis; 2008 Feb; 29(2):210-20. PubMed ID: 17920284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic Inflammation Increases the Susceptibility to Levodopa-Induced Dyskinesia in 6-OHDA Lesioned Rats by Targeting the NR2B-Medicated PKC/MEK/ERK Pathway.
    Yan A; Song L; Zhang Y; Wang X; Liu Z
    Front Aging Neurosci; 2020; 12():625166. PubMed ID: 33597857
    [No Abstract]   [Full Text] [Related]  

  • 19. Comparison of intrastriatal administration of noradrenaline and l-DOPA on dyskinetic movements: a bilateral reverse in vivo microdialysis study in 6-hydroxydopamine-lesioned rats.
    Buck K; Ferger B
    Neuroscience; 2009 Mar; 159(1):16-20. PubMed ID: 19146929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. L-DOPA-induced dyskinesia in a rat model of Parkinson's disease is associated with the fluctuational release of norepinephrine in the sensorimotor striatum.
    Wang Y; Wang HS; Wang T; Huang C; Liu J
    J Neurosci Res; 2014 Dec; 92(12):1733-45. PubMed ID: 24975553
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.